Hormonal
Acarbose treatment reduces the risk of myocardial infarction and any cardiovascular events in type 2 diabetic patients.
If you have type 2 diabetes, acarbose, taken three times daily with meals, may significantly lower your risk of heart attacks and other cardiovascular events. This benefit appears even if you are already taking other heart medications. The drug works by reducing the spike in blood sugar after eating, which may protect your blood vessels.
The treatment significantly reduced the risk for ‘myocardial infarction’ (hazards ratio=0.36 [95% Cl 0.16–0.80], P=0.0120) and ‘any cardiovascular event’ (0.65 [95% Cl 0.48–0.88], P=0.0061).
Why this rating
Meta-analysis of seven randomized, double-blind, placebo-controlled trials provides high-quality evidence, though the studies are older and the population is specific.
Source
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
M Hanefeld · European Heart Journal · 2003
DOI 10.1016/s0195-668x(03)00468-8
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →